In reply
We appreciate Dr Mohammadhosseini's comments regarding our study.1 Our primary end point was complications and not recurrence. For recurrence to be the end point, the study will require enrolling 586 patients (assuming a 10% drop-out rate) to detect an 8% difference between the 2 groups, with a power of 80%, α = .05, a follow-up of at least 3 years, and a budget calculated at more than $5 million.